chr9-98826925-G-C

Variant summary

Our verdict is Likely benign. The variant received -2 ACMG points: 2P and 4B. PP3_ModerateBS2

The NM_024642.5(GALNT12):​c.715G>C​(p.Glu239Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000155 in 1,564,888 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.000072 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00016 ( 0 hom. )

Consequence

GALNT12
NM_024642.5 missense

Scores

8
7
4

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:5

Conservation

PhyloP100: 10.0

Publications

1 publications found
Variant links:
Genes affected
GALNT12 (HGNC:19877): (polypeptide N-acetylgalactosaminyltransferase 12) This gene encodes a member of a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases, which catalyze the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to a serine or threonine residue on a polypeptide acceptor in the initial step of O-linked protein glycosylation. Mutations in this gene are associated with an increased susceptibility to colorectal cancer.[provided by RefSeq, Mar 2011]
GALNT12 Gene-Disease associations (from GenCC):
  • colorectal cancer, susceptibility to, 1
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen, Ambry Genetics, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -2 ACMG points.

PP3
MetaRNN computational evidence supports a deleterious effect, 0.884
BS2
High AC in GnomAd4 at 11 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GALNT12NM_024642.5 linkc.715G>C p.Glu239Gln missense_variant Exon 3 of 10 ENST00000375011.4 NP_078918.3 Q8IXK2-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GALNT12ENST00000375011.4 linkc.715G>C p.Glu239Gln missense_variant Exon 3 of 10 1 NM_024642.5 ENSP00000364150.3 Q8IXK2-1
GALNT12ENST00000610463.1 linkn.*146G>C non_coding_transcript_exon_variant Exon 2 of 4 4 ENSP00000477657.1 A0A087WT76
GALNT12ENST00000610463.1 linkn.*146G>C 3_prime_UTR_variant Exon 2 of 4 4 ENSP00000477657.1 A0A087WT76

Frequencies

GnomAD3 genomes
AF:
0.0000723
AC:
11
AN:
152192
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000162
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000935
AC:
16
AN:
171094
AF XY:
0.0000991
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000385
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000201
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000164
AC:
232
AN:
1412696
Hom.:
0
Cov.:
32
AF XY:
0.000139
AC XY:
97
AN XY:
698226
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
32300
American (AMR)
AF:
0.0000269
AC:
1
AN:
37182
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25276
East Asian (EAS)
AF:
0.00
AC:
0
AN:
36910
South Asian (SAS)
AF:
0.0000373
AC:
3
AN:
80438
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
49816
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5648
European-Non Finnish (NFE)
AF:
0.000201
AC:
218
AN:
1086662
Other (OTH)
AF:
0.000171
AC:
10
AN:
58464
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.452
Heterozygous variant carriers
0
14
29
43
58
72
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000723
AC:
11
AN:
152192
Hom.:
0
Cov.:
32
AF XY:
0.0000538
AC XY:
4
AN XY:
74346
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41456
American (AMR)
AF:
0.00
AC:
0
AN:
15292
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5176
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4828
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10624
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.000162
AC:
11
AN:
68028
Other (OTH)
AF:
0.00
AC:
0
AN:
2090
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.489
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000198
Hom.:
0
Bravo
AF:
0.0000907
ExAC
AF:
0.0000342
AC:
4

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:2
Apr 12, 2024
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The GALNT12 c.715G>C (p.Glu239Gln) variant has been reported in the published literature in an individual with rectal cancer and found to cause an approximately 2-fold decrease in GALNT12 enzyme activity in vitro, however the data lacked statistical significance (PMID: 29749045 (2018)). The frequency of this variant in the general population, 0.00019 (16/84952 chromosomes in European (Non-Finnish) subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -

Jun 12, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 239 of the GALNT12 protein (p.Glu239Gln). This variant is present in population databases (rs777144221, gnomAD 0.02%). This missense change has been observed in individual(s) with rectal cancer (PMID: 29749045). ClinVar contains an entry for this variant (Variation ID: 485652). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GALNT12 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects GALNT12 function (PMID: 29749045). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Colorectal cancer, susceptibility to, 1 Uncertain:2
Oct 31, 2018
Fulgent Genetics, Fulgent Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 07, 2024
Baylor Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Uncertain:1
Apr 10, 2025
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.E239Q variant (also known as c.715G>C), located in coding exon 3 of the GALNT12 gene, results from a G to C substitution at nucleotide position 715. The glutamic acid at codon 239 is replaced by glutamine, an amino acid with highly similar properties. This alteration was identified in a population-based colorectal cancer cohort. Authors performed a functional study assessing enzyme activity and determined that p.E239Q resulted in an approximate 2-fold decrease in enzyme activity; however, this was below the threshold for significance and not considered deleterious (Evans DR et al. Hum. Mutat. 2018 Aug;39(8):1092-1101). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.47
BayesDel_addAF
Uncertain
0.069
T
BayesDel_noAF
Pathogenic
0.14
CADD
Pathogenic
30
DANN
Uncertain
1.0
DEOGEN2
Benign
0.26
T
Eigen
Pathogenic
0.96
Eigen_PC
Pathogenic
0.95
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Uncertain
0.96
D
M_CAP
Benign
0.034
D
MetaRNN
Pathogenic
0.88
D
MetaSVM
Uncertain
-0.020
T
MutationAssessor
Pathogenic
3.0
M
PhyloP100
10
PrimateAI
Benign
0.33
T
PROVEAN
Uncertain
-2.9
D
REVEL
Uncertain
0.57
Sift
Pathogenic
0.0
D
Sift4G
Pathogenic
0.0
D
Polyphen
1.0
D
Vest4
0.94
MVP
0.94
MPC
0.63
ClinPred
0.62
D
GERP RS
5.9
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.84
gMVP
0.71
Mutation Taster
=7/93
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs777144221; hg19: chr9-101589207; API